Author:
Khimani Namrata,Narang Sanjeet
Publisher
Springer International Publishing
Reference15 articles.
1. Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol. 2005;16:825–33.
2. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–9.
3. Medicare Coverage Issues Manual. Coverage issues—durable medical equipment.
www.cms.hhs.gov/manuals/downloads/Pub06_PART_60.pdf
. Accessed 19 Oct 2015.
4. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference-2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):420–35.
5. Yoshida GM, Nelson RW, Capen DA, Nagelberg S, Thomas JC, Rimoldi RL, Haye W. Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes. Am J Orthop. 1996;25:693–4.